Collagen Solutions PLC Introduces new online sales initiative in the US

TIDMCOS

Collagen Solutions PLC

20 March 2017

Collagen Solutions Plc

(the "Company" or the "Group")

Collagen Solutions introduces new online sales initiative in the US

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, has launched a new B to C web-based business in the US to sell standard collagen products directly to end users in the research market.

This is an important initiative for the company as it directly connects Collagen Solutions with end users in a cost effective manner while simultaneously addressing the purchasing needs of researchers. Further, understanding the evolving requirements of this customer segment will help to ensure that the company is supplying the right products for the right markets. From the point of view of the end user, having easy access to medical grade collagen from the outset will help the transition from a research project to a full blown medical device.

Commenting on the new online store, Jamal Rushdy, CEO of Collagen Solutions said: "This initiative serves three purposes for Collagen Solutions. First, it increases our access to the estimated US$200m global market for cell culture reagents. Secondly, it gives us a direct link with the end users of our products so that we can understand their needs and how the market for collagen is evolving. Finally, it establishes Collagen Solutions as the go-to collagen supplier among investigators whose research will guide the rapidly advancing world of regenerative medicine."

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For additional information on the benefits of Collagen Solutions products for research, please visit:

https://www.researchgate.net/institution/Collagen_Solutions/post/5899edb93d7f4b8dfc79d560_Ultra-Pure_Collagen_Biomaterials_to_Progress_Your_Research

As a reminder, Jamal Rushdy, CEO of collagen Solutions will be hosting an investor event today, Monday 20 March, commencing at 4.30 at the Rocket Bar, 6 Adams Court, Old Broad Street, EC2N 1DX. After a formal presentation on the prospects for the Company going forward, Jamal will be available to answer individual questions over refreshments. If you have not already informed us and would like to attend, please contact: [e-mail] to reserve a place.

Enquiries:

 
  Collagen Solutions Plc                                            Contact via Walbrook 
 Jamal Rushdy, Chief Executive 
  Officer 
 Gill Black, Chief Financial 
  Officer 
 
 Cenkos Securities plc (Nominated                                     Tel: [phone] 
  Adviser and Broker) 
  Stephen Keys 
  Steve Cox 
 
 Walbrook PR                               Tel: [phone] or [e-mail] 
 Mike Wort                                                            Mob: [phone] 
 Anna Dunphy                                                          Mob: [phone] 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALIFSTVDIIFID

(END) Dow Jones Newswires

March 20, 2017 04:56 ET (08:56 GMT)